Harlan Waksal - Mar 18, 2024 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
Executive Chair, Director
Signature
/s/ Jason Cavalier, Attorney-in-Fact for Harlan Waksal, M.D.
Stock symbol
LYRA
Transactions as of
Mar 18, 2024
Transactions value $
$0
Form type
4
Date filed
3/20/2024, 07:21 PM
Previous filing
Nov 13, 2023
Next filing
Jun 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYRA Common Stock Award $0 +275K +104.98% $0.00 537K Mar 18, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on January 31, 2025.